Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Cosmeceutical Aptitudes of Azelaic Acid

Author(s): Supriya Kumari Singh, Saumya Chaubey, Anil Bansal, Gurpreet Kaur and Deepinder Singh Malik*

Volume 13, Issue 3, 2021

Published on: 26 May, 2021

Page: [222 - 229] Pages: 8

DOI: 10.2174/2589977513666210526122909

Price: $65

conference banner
Abstract

Azelaic acid (AZA) is a white crystalline dicarboxylic acid naturally found in grains, rye, and barley. AZA has substantial biological and therapeutic abilities (viz a viz) its anti-inflammatory, anti-oxidant, anti-keratinizing, anti-microbial properties, etc., which contribute to its applicability in the management of mild to harsh dermatological complications (acne, rosacea, dermatitis, hyper-pigmentation, carcinomas, etc.). AZA has shown its effectiveness against varied non-inflammatory and inflammatory lesions by normalizing hyper-keratinization state and attenuating the increased levels of microbial content. Topically AZA, either alone or in conjunction with other active moieties, has proved to effectively prevent acne and several other hyper-pigmentary conditions. Chronic applicability of AZA has been evidenced with the effects like itching, burning, stinging, redness, etc. To deal with the former issues, research is being conducted to substitute the conventional formulations with novel preparations (liposome’s, niosomes, micro sponges, lipid nanocarriers, etc.), which could enhance the overall pharmaceutical and pharmacological profile of the drug. This article is an attempt to highlight the basic physiochemical properties of AZA, its physiological role (especially in dermatology), various commercial preparations and recent novel approaches that are in research with an aim to augment the therapeutic and safety profile of AZA.

Keywords: Acne, anti-hyper-pigmenting, anti-keratinizing, azelaic acid, lipid nano-carrier, Propionibacterium acnes.

« Previous Next »
Graphical Abstract

[1]
Zaldman B, Kisilev A, Garti N. Double bond oxidation of unsaturated fatty acids. J Am Oil Chem Soc 1988; 65: 611-5.
[http://dx.doi.org/10.1007/BF02540689]
[2]
Brenna E, Colombo D, Lecce G, et al. Conversion of oleic acid into azelaic and pelargonic acid by a chemo-enzymatic route. Molecules 2020; 25(8): 1-11.
[http://dx.doi.org/10.3390/molecules25081882] [PMID: 32325747]
[3]
Nazzaro-Porro M, Passi S, Picardo M, Breathnach A, Clayton R, Zina G. Beneficial effect of 15% azelaic acid cream on Acne vulgaris. Br J Dermatol 1983; 109(1): 45-8.
[http://dx.doi.org/10.1111/j.1365-2133.1983.tb03990.x] [PMID: 6222755]
[4]
Breathnach AS, Nazzaro-Porro M, Passi S. Azelaic acid. Br J Dermatol 1984; 111(1): 115-20.
[http://dx.doi.org/10.1111/j.1365-2133.1984.tb04025.x] [PMID: 6234914]
[5]
Bladon PT, Burke BM, Cunliffe WJ, Forster RA, Holland KT, King K. Topical azelaic acid and the treatment of acne: a clinical and laboratory comparison with oral tetracycline. Br J Dermatol 1986; 114(4): 493-9.
[http://dx.doi.org/10.1111/j.1365-2133.1986.tb02856.x] [PMID: 2938615]
[6]
Norris JFB, Burke BM, Cunliffe WJ. A comparison of topical Azelaic acid and its base in the treatment of acne and related disorders. 1990; pp. 237-40.
[7]
Cunliffe WJ, Holland KT. Clinical and laboratory studies on 20% azelaic acid cream therapy for acne In: Breathnach KA, Graupe GS, Eds. Azelaic Acid: A new therapeutic agent. Acta Derm Venereol Suppl (Stockh) 1989; 143: pp. 31-4.
[PMID: 2528256]
[8]
Mayer-da-Silva A, Gollnick H, Detmar M, et al. Effects of azelaic acid on sebaceous glands, sebum excretion rate and keratinization pattern in human skin. An in-vivo and in-vitro study. Acta Derm Venereol Suppl (Stockh) 1989; 143: 20-30.
[PMID: 2475995]
[9]
Cavicchini S, Caputo R. Long term therapy with 20% Azelaic acid cream in acne. Acta Derm Venereol Suppl (Stockh) 1989; 143: 40-4.
[PMID: 2528258]
[10]
Hjorth N, Graupe K. Azelaic acid in the treatment of acne a clinical comparison with oral tetra-cyclines. Acta Derm Venereol Suppl (Stockh) 1989; 143: 45-8.
[PMID: 2528259]
[11]
Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% Azelaic acid cream in acne: Comparison with vehicle and tretinoin. In: Acta Derm Venereol Suppl (Stockh). 1989; 143: pp. 35-9.
[PMID: 2528257]
[12]
Nazzaro-Porro M, Passi S. Effetto deglia cididi carbossilici in alcune dermatosi pigmentarie. G Ital Dermatol 1978; 113: 401-4.
[13]
Nazzaro PM. Azelaic acid. J Am Acad Dermatol 1987; 17(6): 1033-41.
[http://dx.doi.org/10.1016/S0190-9622(87)70294-1] [PMID: 2963038]
[14]
Ertle T, Wiskemann A, Janner M. Local treatment of lentigo maligna with azelaic acid. Arch Dermatol Res 1981; 271: 197-203.
[http://dx.doi.org/10.1007/BF00412547]
[15]
Robinson JK. Margin control for lentigo maligna. J Am Acad Dermatol 1994; 31(1): 79-85.
[http://dx.doi.org/10.1016/S0190-9622(94)70140-7] [PMID: 8021377]
[16]
Nazzaro-Porro M, Passi S, Zina G, et al. Effect of azelaic acid on human malignant melanoma. Lancet 1980; 1(8178): 1109-11.
[http://dx.doi.org/10.1016/S0140-6736(80)91555-X] [PMID: 6103442]
[17]
Bojar RA, Holland KT, Leeming JP, Cunliffe WJ. Azelaic acid: its uptake and mode of action in Staphylococcus epidermidis NCTC 11047. J Appl Bacteriol 1988; 64(6): 497-504.
[http://dx.doi.org/10.1111/j.1365-2672.1988.tb02441.x] [PMID: 2459099]
[18]
King K, Leeming JP, Holland KT, Cunliffe WJ. The effect of Azelaic acid on cutaneous micro-flora in-vivo and in-vitro. J Invest Dermatol 1985; 84: 438.
[19]
Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res 1991; 283(3): 162-6.
[http://dx.doi.org/10.1007/BF00372056] [PMID: 1867478]
[20]
Passi S, Picardo M, Zompetta C, De Luca C, Breathnach AS, Nazzaro-Porro M. The oxyradical-scavenging activity of azelaic acid in biological systems. Free Radic Res Commun 1991; 15(1): 17-28.
[http://dx.doi.org/10.3109/10715769109049121] [PMID: 1769610]
[21]
Grange PA, Chéreau C, Raingeaud J, et al. Production of superoxide anions by keratinocytes initiates P. acnes-induced inflammation of the skin. PLoS Pathog 2009; 5(7): e1000527.
[http://dx.doi.org/10.1371/journal.ppat.1000527] [PMID: 19629174]
[22]
Mastrofrancesco A, Ottaviani M, Aspite N, et al. Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARgamma activation. Exp Dermatol 2010; 19(9): 813-20.
[http://dx.doi.org/10.1111/j.1600-0625.2010.01107.x] [PMID: 20545756]
[23]
Briganti S, Flori E, Mastrofrancesco A, et al. Azelaic acid reduced senescence-like phenotype in photo-irradiated human dermal fibroblasts: Possible implication of PPARγ. Exp Dermatol 2013; 22(1): 41-7.
[http://dx.doi.org/10.1111/exd.12066] [PMID: 23278893]
[24]
Yamasaki K, Gallo RL. Azelaic acid (AzA) gel 15% alters kallikrein 5 in epidermal keratinocytes: critical elements in production of cathhelicidin and the pathogenesis of rosacea. Dermatologist 2010; 18: 26-38.
[25]
Schauber J. Antimicrobial peptides, Vitamin D3 and more. How rosacea may develop. Hautarzt 2011; 62(11): 815-9.
[http://dx.doi.org/10.1007/s00105-011-2142-9] [PMID: 22002717]
[26]
Nazzaro-Porro M, Passi S. Identification of tyrosinase inhibitors in cultures of pityrosporum. J Invest Dermatol 1978; 71(3): 205-8.
[http://dx.doi.org/10.1111/1523-1747.ep12547184] [PMID: 99481]
[27]
Jeremy AHT, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003; 121(1): 20-7.
[http://dx.doi.org/10.1046/j.1523-1747.2003.12321.x] [PMID: 12839559]
[28]
Passi S, Picardo M, Nazzaro-Porro M, Breathnach A, Confaloni AM, Serlupi-Crescenzi G. Antimitochondrial effect of saturated medium chain length (C8-C13) dicarboxylic acids. Biochem Pharmacol 1984; 33(1): 103-8.
[http://dx.doi.org/10.1016/0006-2952(84)90376-9] [PMID: 6704136]
[29]
Melnik BC, Schmitz G, Zouboulis CC. Anti-acne agents attenuate FGFR2 signal transduction in acne. J Invest Dermatol 2009; 129(8): 1868-77.
[http://dx.doi.org/10.1038/jid.2009.8] [PMID: 19225542]
[30]
Detmar M, Mayer-da-Silva A, Stadler R, Orfanos CE. Effects of azelaic acid on proliferation and ultrastructure of mouse keratinocytes in vitro. J Invest Dermatol 1989; 93(1): 70-4.
[http://dx.doi.org/10.1111/1523-1747.ep12277353] [PMID: 2473140]
[31]
Gollnick H, Mayer-da-Silva A, Orfanos CE. Effects of Azelaic acid on filaggrin, other cytokeratins and on the ultra-structure of human keratinocytes in vivo. J Invest Dermatol 1989; 89: 452.
[32]
Maple PA, Hamilton-Miller JM, Brumfitt W. Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1992; 29(6): 661-8.
[http://dx.doi.org/10.1093/jac/29.6.661] [PMID: 1506349]
[33]
Bojar RA, Cutcliffe AG, Graupe K, Cunliffe WJ, Holland KT. Follicular concentrations of azelaic acid after a single topical application. Br J Dermatol 1993; 129(4): 399-402.
[http://dx.doi.org/10.1111/j.1365-2133.1993.tb03165.x] [PMID: 8217752]
[34]
Janota-Bassalik L, Wright LD. Azelaic acid utilization by a pseudomonas. J Gen Microbiol 1964; 36: 405-14.
[http://dx.doi.org/10.1099/00221287-36-3-405] [PMID: 14217352]
[35]
Charnock C, Brudeli B, Klaveness J. Evaluation of the antibacterial efficacy of diesters of azelaic acid. Eur J Pharm Sci 2004; 21(5): 589-96.
[http://dx.doi.org/10.1016/j.ejps.2003.12.006] [PMID: 15066659]
[36]
Bojar RA, Cunliffe WJ, Holland KT. Disruption of the transmembrane pH gradient: A possible mechanism for the antibacterial action of azelaic acid in Propionibacterium acnes and Staphylococcus epidermidis. J Antimicrob Chemother 1994; 34(3): 321-30.
[http://dx.doi.org/10.1093/jac/34.3.321] [PMID: 7829407]
[37]
Holland KT, Bojar RA. Antimicrobial effects of azelaic acid. J Dermatolog Treat 1993; 4: S8-S11.
[http://dx.doi.org/10.3109/09546639309082152]
[38]
Bojar RA, Cutcliffe AG, Graupe K, Cunliffe WJ, Holland KT. Azelaic acid: a review of its antimicrobial properties. Rev Contemp Pharmacother 1993; 4: 403-14.
[39]
Bojar RA, Holland KT, Cunliffe WJ. The in-vitro antimicrobial effects of azelaic acid upon Propionibacterium acnes strain P37. J Antimicrob Chemother 1991; 28(6): 843-53.
[http://dx.doi.org/10.1093/jac/28.6.843] [PMID: 1726169]
[40]
Breathnach AS, Robins EJ, Pätzold HC, et al. Effect of dicarboxylic acids (C6 and C9) on human choroidal melanoma in cell culture. Invest Ophthalmol Vis Sci 1989; 30(3): 491-8.
[PMID: 2925320]
[41]
Breathnach AS, Robins EJ, Bhasin Y, et al. Observations on cell kinetics and viability of a human melanoma cell line exposed to dicarboxylic acids in tissue culture. Histol Histopathol 1986; 1(3): 235-9.
[PMID: 2980117]
[42]
Geier G, Hauschild T, Bauer R, Kreysel HW. Effect of azelaic acid on the growth of melanoma cell cultures in comparison with fibroblast cultures. Hautarzt 1986; 37(3): 146-8.
[PMID: 3700102]
[43]
Leibl H, Stingl G, Pehamberger H, Korschan H, Konrad K, Wolff K. Inhibition of DNA synthesis of melanoma cells by azelaic acid. J Invest Dermatol 1985; 85(5): 417-22.
[http://dx.doi.org/10.1111/1523-1747.ep12277084] [PMID: 4056455]
[44]
Pathak MA, Ciganek ER, Wick M, Sober AJ, Farinelli WA, Fitzpatrick TB. An evaluation of the effectiveness of azelaic acid as a depigmenting and chemotherapeutic agent. J Invest Dermatol 1985; 85(3): 222-8.
[http://dx.doi.org/10.1111/1523-1747.ep12276684] [PMID: 4031538]
[45]
Robins EJ, Breathnach AS, Bennett D, Ward BJ, Bhasin Y, Ethridge L. Nazzaro- Porro, M.; Passi, S.; Picardo, M. Ultra-structural observations on the effect of Azelaic acid on normal human melanocytes and a human melanoma cell line in tissue culture. Br J Dermatol 1985; 113: 687-97.
[http://dx.doi.org/10.1111/j.1365-2133.1985.tb02404.x] [PMID: 4096883]
[46]
Robins EJ, Breathnach AS, Ward BJ, et al. Effect of dicarboxylic acids on harding-passey and cloudman S91 melanoma cells in tissue culture. J Invest Dermatol 1985; 85(3): 216-21.
[http://dx.doi.org/10.1111/1523-1747.ep12276681] [PMID: 4031537]
[47]
Pätzold HC, Breathnach AS, Robins EJ, et al. Effect of dicarboxylic (C6 and C9) acids on a human squamous carcinoma cell line in culture. Histol Histopathol 1989; 4(2): 167-71.
[PMID: 2520453]
[48]
Picardo M, Passi S, Sirianni MC, et al. Activity of azelaic acid on cultures of lymphoma- and leukemia-derived cell lines, normal resting and stimulated lymphocytes and 3T3 fibroblasts. Biochem Pharmacol 1985; 34(10): 1653-8.
[http://dx.doi.org/10.1016/0006-2952(85)90630-6] [PMID: 4004885]
[49]
Fitton A, Goa KL. Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 1991; 41(5): 780-98.
[http://dx.doi.org/10.2165/00003495-199141050-00007] [PMID: 1712709]
[50]
Hu F, Mah K, Teramura DJ. Effects of dicarboxylic acids on normal and malignant melanocytes in culture. Br J Dermatol 1986; 114(1): 17-26.
[http://dx.doi.org/10.1111/j.1365-2133.1986.tb02775.x] [PMID: 3942687]
[51]
Ward BJ, Breathnach AS, Robins EJ, et al. Effect of L-carnitine on cultured murine melanoma cells exposed to azelaic acid. J Invest Dermatol 1986; 86(4): 438-41.
[http://dx.doi.org/10.1111/1523-1747.ep12285783] [PMID: 3745962]
[52]
Nazzaro-Porro M, Passi S, Balus L, Breathnach A, Martin B, Morpurgo G. Effect of dicarboxylic acids on lentigo maligna. J Invest Dermatol 1979; 72(6): 296-305.
[http://dx.doi.org/10.1111/1523-1747.ep12531744] [PMID: 448162]
[53]
Mayer-da Silva A, Gollnick H, Imcke E, Orfanos CE. Azelaic acid vs. placebo: effects on normal human keratinocytes and melanocytes. Electron microscopic evaluation after long-term application in vivo. Acta Derm Venereol 1987; 67(2): 116-22.
[PMID: 2438874]
[54]
Wilkerson MG, Wilkin JK. Azelaic acid esters do not depigment pigmented guinea pig skin. Arch Dermatol 1990; 126(2): 252-3.
[http://dx.doi.org/10.1001/archderm.126.2.252] [PMID: 2301969]
[55]
Hjorth N, Graupe K. Azelaic acid for the treatment of acne. A clinical comparison with oral tetracycline. Acta Derm Venereol Suppl (Stockh) 1989; 143: 45-8.
[PMID: 2528259]
[56]
Breathnach AC, Nazzaro-Porro M, Passi S, Zina G. Azelaic acid therapy in disorders of pigmentation. Clin Dermatol 1989; 7(2): 106-19.
[http://dx.doi.org/10.1016/0738-081X(89)90061-8] [PMID: 2667735]
[57]
Nazzaro-Porro M, Passi S, Zina G, Breathnach AS. Ten years’ experience of treating lentigo maligna with topical azelaic acid. Acta Derm Venereol Suppl (Stockh) 1989; 143: 49-57.
[PMID: 2773614]
[58]
McLean DI, Peter KK. Apparent progression of lentigo maligna to invasive melanoma during treatment with topical azelaic acid. Br J Dermatol 1986; 114(6): 685-9.
[http://dx.doi.org/10.1111/j.1365-2133.1986.tb04876.x] [PMID: 3718862]
[59]
Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% Azelaic acid cream in the treatment of acne vulgaris: Comparison with vehicle and topical tretinoin. Acta DermVenereol 1989; 143: 35-9.
[60]
Cavicchini S, Caputo R. Long-term treatment of acne with 20% azelaic acid cream. Acta Derm Venereol Suppl (Stockh) 1989; 143: 40-4.
[PMID: 2528258]
[61]
Graupe K, Zaumseil RP. Skinoren- a new topical therapeutic agent for the treatment of acne vulgaris. Jahrbuch der Dermatologie, Wissenschaftliche Verlagsgesellschaft Biermann, 1991.
[62]
Gollnick H, Graupe K. Azelaic acid for the treatment of acne: comparative trials. J Dermatolog Treat 1989; 1: 27-30.
[http://dx.doi.org/10.3109/09546638909094478]
[63]
Mingrone G, Greco AV, Nazzaro-Porro M, Passi S. Toxicity of azelaic acid. Drugs under Exp Clin Res 1983; 9: 447-55.
[64]
Verallo-Rowell VM, Verallo V, Graupe K, Lopez-Villafuerte L, Garcia-Lopez M. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh) 1989; 143: 58-61.
[PMID: 2528260]
[65]
Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013; 65(1): 36-48.
[http://dx.doi.org/10.1016/j.addr.2012.09.037] [PMID: 23036225]
[66]
Choi MJ, Maibach HI. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol 2005; 18(5): 209-19.
[http://dx.doi.org/10.1159/000086666] [PMID: 16015019]
[67]
Shaha V, Jain H, Krishna J, Patel P. Micro sponge drug delivery: a review. Int J Res Pharm Sci 2010; 1: 212-8.
[68]
Lovelyn C, Attama AA. Current state of nano-emulsions in drug delivery. J Biomater Nanobiotechnol 2011; 2: 626.
[http://dx.doi.org/10.4236/jbnb.2011.225075]
[69]
Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 2003; 255(1-2): 13-32.
[http://dx.doi.org/10.1016/S0378-5173(03)00087-5] [PMID: 12672598]
[70]
Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366(1-2): 170-84.
[http://dx.doi.org/10.1016/j.ijpharm.2008.10.003] [PMID: 18992314]
[71]
Kusumawardani A, Paramitasari AR, Dewi SR, Betaubun AI. The application of liposomal azelaic acid, 4-n butyl resorcinol and retinol serum enhanced by microneedling for treatment of malar pattern melasma: a case series. Dermatol Rep 2019; 11(s1)
[http://dx.doi.org/10.4081/dr.2019.8075]
[72]
Burchacka E, Potaczek P, Paduszyński P, Karłowicz-Bodalska K, Han T, Han S. New effective azelaic acid liposomal gel formulation of enhanced pharmaceutical bioavailability. Biomed Pharmacother 2016; 83: 771-5.
[http://dx.doi.org/10.1016/j.biopha.2016.07.014] [PMID: 27484346]
[73]
Al-Marabeh S, Khalil E, Khanfar M, Al-Bakri AG, Alzweiri M. A prodrug approach to enhance azelaic acid percutaneous availability. Pharm Dev Technol 2017; 22(4): 578-86.
[http://dx.doi.org/10.1080/10837450.2016.1200614] [PMID: 27346659]
[74]
Apriani EF, Rosana Y, Iskandarsyah I. Formulation, characterization, and in vitro testing of azelaic acid ethosome-based cream against Propionibacterium acnes for the treatment of acne. J Adv Pharm Technol Res 2019; 10(2): 75-80.
[http://dx.doi.org/10.4103/japtr.JAPTR_289_18] [PMID: 31041186]
[75]
Mistry A, Ravikumar P. Development, and evaluation of azelaic acid based ethosomes for topical delivery for the treatment of acne. Ind J Pharm Educ Res 2016; 50: S232-43.
[http://dx.doi.org/10.5530/ijper.50.3.34]
[76]
Rahmi AD, Pangesti DM. Comparison of the characteristics of transfersomes and protransfersomes containing Azelaic acid. J Young Pharm 2018; 10(2s): S11-5.
[77]
Heidari A. Formulation and physicochemical evaluation of niosomal azelaic acid in topical cream base. Doctoral dissertation. Kerman, Iran: School of Pharmacy, Kerman University of Medical Sciences 2019.
[78]
Mofrad I. Formulation & physicochemical evaluation of niosomal azelaic acid in topical gel base. Doctoral dissertation. Kerman, Iran: School of Pharmacy, Kerman University of Medical Sciences 2018.
[79]
Ma H, Yu M, Tan F, Li N. Improved percutaneous delivery of azelaic acid employing micro emulsion as nanocarrier: formulation optimization, in-vitro and in-vivo evaluation. RSC Advances 2015; 5: 28985-95.
[http://dx.doi.org/10.1039/C5RA00713E]
[80]
Quaresma S, André V, Antunes AM, et al. Novel antibacterial azelaic acid BioMOFs. Cryst Growth Des 2019; 20: 370-82.
[http://dx.doi.org/10.1021/acs.cgd.9b01302]
[81]
Lacatusu I, Badea G, Popescu M, et al. Marigold extract, azelaic acid and black caraway oil into lipid nanocarriers provides a strong anti-inflammatory effect in vivo. Ind Crop Prod 2017; 109: 141-50.
[http://dx.doi.org/10.1016/j.indcrop.2017.08.030]
[82]
Malik DS, Kaur G. Nano-structured gel for topical delivery of azelaic acid: designing, characterization, and in-vitro evaluation. J Drug Deliv Sci Technol 2018; 47: 123-36.
[http://dx.doi.org/10.1016/j.jddst.2018.07.008]
[83]
Tomić I, Juretić M, Jug M, Pepić I, Cetina Čižmek B, Filipović- Grčić J. Preparation of in situ hydrogels loaded with azelaic acid nanocrystals and their dermal application performance study. Int J Pharm 2019; 563: 249-58.
[http://dx.doi.org/10.1016/j.ijpharm.2019.04.016] [PMID: 30965120]

Rights & Permissions Print Cite
Article Metrics
31
1
© 2024 Bentham Science Publishers | Privacy Policy